A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
ApexOnco Front Page
Recent articles
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
But biomarker enrichment and toxicity remain key for FX-909.
The month saw the first commissioner's priority voucher approval in oncology.
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
The company will license EGFR and cMet inhibitors from Celyn.
